Business · 17/11/20261 min read
Tryngolza™ (olezarsen) approved in the EU for severe hypertriglyceridaemia (sHTG)
Summary
Tryngolza is now the first and only RNA-targeted therapy indicated in the EU for sHTG ≥880 mg/dL (≥10 mmol/L) EC decision is based on Phase 3 CORE and CORE2 results, demonstrating a statistically significant mean reduction of up to 73% in triglyceride levels at 6 months and a significant...